Su2008 Blood Bioprofiles For The Diagnosis of Intestinal Metaplasia and Gastric Cancer

Background and aims: Adjuvant oxaliplatin-based chemotherapy is widely used for stage III colorectal cancer (CRC) after curative surgery.CRC is a molecularly heterogeneous disease, and our current knowledge of therapeutic response-related genetic factors remains limited.GALNT14-rs9679162 genotype is a prognostic predictor for chemotherapy response in advanced hepatocellular carcinoma.Here, we investigated whether this genotype was related to the therapeutic outcome of stage III CRC. Materials and Methods: A cohort of 300 stage III CRC patients receiving curative resection followed by oxaliplatin-based chemotherapy was retrospectively recruited.GALNT14 genotypes and the clinicopathological factors were correlated with post-therapeutic prognosis.Results: Of these patients, 18% patients had GALNT14-rs9679162 "TT" and 82% had the "GT" + "GG" genotypes.The analysis showed that the "TT" genotype was associated with unfavorable overall survival (OS, P = 0.009) but not with recurrence free survival (RFS, P = 0.700).Subgroup analysis showed that the "TT" genotype was associated with unfavorable OS in the following subgroups: age £ 65 years, male, left side CRC, N2 stage, CEA > 5 ng/ml, and mucinous histology (P = 0.012, 0.011, 0.009, 0.025, 0.013, and 0.007, respectively).Within the latter 2 subgroups, the "TT" genotype was the only independent predictor for OS.Finally, the "TT" genotype was associated with the T4 tumor stage (P = 0.017) and in patients with T4 tumors, the "TT" genotype was the only independent predictor for unfavorable RFS (P = 0.007).Conclusions: GALNT14 "TT" genotype was associated with unfavorable OS in stage III CRC patients receiving curative surgery and adjuvant oxaliplatin-based chemotherapy.